257 related articles for article (PubMed ID: 32873088)
1. The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088
[TBL] [Abstract][Full Text] [Related]
2. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
3. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
10. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract][Full Text] [Related]
12. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
13. Management of polycythemia vera: A survey of treatment patterns in Italy.
Palumbo GA; Breccia M; Baratè C; Bonifacio M; Elli EM; Iurlo A; Pugliese N; Rossi E; Guglielmelli P; Palandri F
Eur J Haematol; 2023 Feb; 110(2):161-167. PubMed ID: 36319575
[TBL] [Abstract][Full Text] [Related]
14. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
15. ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation.
Prescrire Int; 2016 Oct; 25(175):229-231. PubMed ID: 30645821
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
Kuykendall AT
Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Griesshammer M; Saydam G; Palandri F; Benevolo G; Egyed M; Callum J; Devos T; Sivgin S; Guglielmelli P; Bensasson C; Khan M; Ronco JP; Passamonti F
Ann Hematol; 2018 Sep; 97(9):1591-1600. PubMed ID: 29804268
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
